Nordic digital therapeutics company SidekickHealth has entered into a strategic partnership with German pharmaceutical and life science company Bayer to provide a digital medication management and lifestyle change platform to patients suffering from Peripheral Artery Disease (PAD).
Sidekick specializes in the creation of gamified digital therapeutic (DTx) solutions and programs, transforming chronic disease management across multiple therapeutic areas in alliance with key stakeholders in the pharmaceutical and healthcare industries.
“Bayer continues to be at the forefront in the transformation of medicine, and we are thrilled to partner with them to deliver innovative therapies for people with lifestyle-related diseases,” said Tryggvi Thorgeirsson, M.D., MPH, Co-Founder, and CEO of SidekickHealth.
Sidekick and Bayer plan to launch the program in Sweden, with the aim to roll it out in other European markets, collaborating with key opinion leaders and clinical experts in PAD, including the President of the Swedish Society of Vascular Surgery Dr. Carl Wahlgren.
“Lifestyle change is at the heart of what we do, and our programs can have a multiplier effect on the positive outcomes of medical care and the world’s best medicines. We reinforce medication adherence and use it as a gateway to bring about a positive lifestyle change in a much broader sense. We are excited to be working with Bayer to help patients take the first step and beyond,” Thorgeirsson added.